ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2155 entries already.
In autumn, stakeholders across the globe pledged to take more action in the fight against antimicrobial resistance (AMR). Whereas from the push side new public and private initiatives appeared on the screen, discussion about which pull mechanism should be started first is in full swing. Meanwhile, small and medium-sized companies combine forces aiming to propel preclinical and early clinical R&D.
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics’ WuXiBody platform.
An analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
British drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
LSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
GlaxoSmithKline said it will pay $75 per share in cash to take over US oncology player Tesaro, whose FDA-approved DNA repair blocker nirparib (Zejula) made only US$166m in sales in Q1-3/2018.
Janssen affiliate Cilag GmbH International has licenced argenx’ anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.
Diagnostic results must be readily available to diagnose critically ill patients in emergency settings and at ICUs. So far, diagnostic blood tests, which demonstrably could help emergency meds recognise residual congestion in heart failure, septic shock, or acute kidney injury before patients reach critical condition, have not been available in the automated format required at ICUs. After Sphingotec acquired Nexus IB-10 POC testing platform in May, investors wait in line.